Drug intelligence / Profile preview

ET356

Development stage: Unknown
Lead developer: Expression Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ET356 is an investigational chimeric antigen receptor T cell (CAR-T) therapy developed by Expression Therapeutics. It is being studied primarily for the treatment of neoplasms, immune system diseases, and hemic and lymphatic diseases, with a particular focus on T-cell lymphoma. As a CAR-T therapy, ET356 involves engineering a patient's own T cells to express a synthetic receptor that targets specific antigens on malignant cells, enabling targeted immune-mediated destruction of those cancerous or diseased cells[1][2].

Beyond the preview

Go deeper on ET356.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ET356.

Explore the full profile